Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study.
D001711:Biotransformation; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology*; D009173:Mycophenolic Acid / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D012449:Safety; D013608:Tablets, Enteric-Coated; D013997:Time Factors
D007166:Immunosuppressive Agents; D013608:Tablets, Enteric-Coated; D009173:Mycophenolic Acid